CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Pointe-à-Pitre, France.
Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Int J Cancer. 2020 Feb 1;146(3):657-663. doi: 10.1002/ijc.32287. Epub 2019 Apr 8.
Previous studies have suggested that exposure to environmental chemicals with hormonal properties, also called endocrine disrupting chemicals, may be involved in the occurrence of prostate cancer (PCa). Such exposure may also influence the treatment outcome as it is still present at the time of diagnosis, the beginning of therapy, and beyond. We followed 326 men in Guadeloupe (French West Indies) who underwent radical prostatectomy as primary treatment of localized PCa. We analyzed the relationship between exposure to the estrogenic chlordecone, the antiandrogenic dichlorodiphenyldichloroethylene (DDE, the main metabolite of the insecticide DDT), and the nondioxin-like polychlorinated biphenyl congener 153 (PCB-153) with mixed estrogenic/antiestrogenic properties and the risk of biochemical recurrence (BCR) after surgery. After a median follow-up of 6.1 years after surgery, we found a significant increase in the risk of BCR, with increasing plasma chlordecone concentration (adjusted hazard ratio = 2.51; 95% confidence interval: 1.39-4.56 for the highest vs. lowest quartile of exposure; p trend = 0.002). We found no associations for DDE or PCB-135. These results shown that exposure to environmental estrogens may negatively influence the outcome of PCa treatment.
先前的研究表明,暴露于具有激素特性的环境化学物质(也称为内分泌干扰化学物质)可能与前列腺癌(PCa)的发生有关。这种暴露也可能影响治疗结果,因为在诊断时、治疗开始时甚至更久之后,它仍然存在。我们随访了 326 名在法属西印度群岛瓜德罗普岛接受根治性前列腺切除术作为局部 PCa 主要治疗的男性。我们分析了暴露于具有混合雌激素/抗雌激素特性的雌激素性氯丹、雄激素性二氯二苯二氯乙烯(DDT 的主要代谢物 DDE)和非二恶英类多氯联苯同系物 153(PCB-153)与手术后生化复发(BCR)风险之间的关系。手术后中位随访 6.1 年后,我们发现随着血浆氯丹浓度的增加,BCR 的风险显著增加(调整后的危险比=2.51;暴露最高四分位与最低四分位相比,95%置信区间为 1.39-4.56;趋势检验 p=0.002)。我们没有发现 DDE 或 PCB-135 的关联。这些结果表明,环境雌激素的暴露可能会对 PCa 治疗的结果产生负面影响。